QNCXQuince Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Quince Therapeutics, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QNCXEsta | $32M#6 | 0.3x#2 | — | — | — | -47.8%#8 | — | — | — | — | -92.4%#8 | — |
| MESO | $18.5B#1 | — | — | 1076.4x#2 | 191.4%#3 | -16.1%#6 | — | — | — | — | -8.4%#3 | — |
| MOLN | $155M#4 | — | — | — | — | — | — | — | — | — | 0.8%#2 | — |
| OKYO | $73M#5 | — | — | — | — | 72.0%#3 | — | — | — | — | -46.4%#4 | — |
| PROK | — | — | — | — | 1075.0%#1 | -12.7%#5 | -18477.8%#5 | — | — | — | -60.0%#5 | — |
| QGEN | $11.0B#2 | 26.2x#3 | 2.9x#2 | 5.3x#1 | 5.7%#5 | 408.3%#1 | 22.3%#1 | 11.2%#1 | 8.8%#1 | 7#1 | 15.6%#1 | 0.5%#1 |
| SABSW | $9099#7 | 0.0x#1 | 0.0x#1 | — | -100.0%#7 | 138.9%#2 | — | 6.2%#2 | — | — | -99.7%#10 | — |
| SCNI | $6.3B#3 | 112.9x#4 | 772.8x#3 | 4776.7x#3 | 99.2%#4 | -273.2%#9 | -575.3%#3 | -102.5%#3 | -110.5%#2 | — | -96.1%#9 | — |
| SGMOQ | — | — | — | — | -31.6%#6 | -25.5%#7 | -306.5%#2 | — | — | — | — | — |
| SLBT | $1#8 | — | — | — | — | — | — | — | — | — | -87.7%#7 | — |
| TCRX | — | — | — | — | 266.7%#2 | -1.8%#4 | -1315.4%#4 | -188.0%#4 | -8271.2%#3 | — | -81.3%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-05.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice